Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: Out with the old, in with the new

Kian Bichoupan, Douglas T. Dieterich

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Introduction: Liver disease is a major burden in patients co-infected with HIV and hepatitis C virus (HCV). From the time of its approval, pegylated-IFNα-2a (pegIFN-α2a) has played a major role in treatment of HCV in HIV/HCV co-infection. Areas covered: This article briefly summarizes the epidemiology of HCV/HIV co-infection, the pharmacokinetic, and pharmacodynamic properties of pegIFN-α2a. Results from clinical trials investigating therapies containing pegIFN-α2a for HIV/HCV co-infected patients will be discussed with a focus on efficacy and safety. Expert opinion: PegIFN-α2a has improved rates of sustained virologic response for co-infected patients. In combination with direct-acting antivirals (DAA), the disparity between mono- and co-infected patients is beginning to disappear. For the first time, IFN-free regimens are available in clinical practice. It is unlikely that pegIFN-α2a will continue to be a critical component in treatments for HCV in the general co-infected population.

Original languageEnglish
Pages (from-to)1369-1378
Number of pages10
JournalExpert Opinion on Biological Therapy
Issue number9
StatePublished - Sep 2014


  • Direct-acting antivirals
  • HIV
  • Hepatitis C virus
  • Pegylated-IFNα-2a


Dive into the research topics of 'Pegylated-IFNα2a for HIV/hepatitis C virus coinfected patients: Out with the old, in with the new'. Together they form a unique fingerprint.

Cite this